Melanoma/Skin Cancer News

Approximately half of patients with metastatic melanoma have BRAF mutations, specifically BRAF V600E and BRAF V600K mutations, that enable tumor cells to grow out of control. Continuous dosing with a combination of BRAF and MEK inhibitors has shown better results than intermittent dosing in these cases, according to recent research, while combination regimens also show promise.

The first two doses of nivolumab with ipilimumab appeared to drive efficacy and toxicity of the combination among certain patients with melanoma, according to phase 2 study results presented during the ASCO20 Virtual Scientific Program.

Aminolevulinic acid 20% combined with photodynamic therapy was more effective in clearing actinic keratoses on the upper extremities, meaning the arms from elbows to base of the fingers, compared to vehicle, according to a poster presented at the American Academy of Dermatology virtual meeting.

Multiple aggregated yellow-white globules were observed in more than one-fifth of basal cell carcinoma cases in a case-control study.

Lifileucel induced high response rates among patients with advanced melanoma whose disease progressed on immune checkpoint and BRAF/MEK inhibitors, according to study results presented during the ASCO20 Virtual Scientific Program.

Lung transplant recipients who were treated with voriconazole to prevent aspergillosis were significantly more likely than those who did not receive voriconazole to develop squamous cell carcinoma, according to a study.

Pembrolizumab plus low-dose ipilimumab demonstrated antitumor activity among patients with advanced melanoma who failed prior treatment, according to phase 2 study results presented during the ASCO20 Virtual Scientific Program.

Melanoma Research Foundation will present its Humanitarian Award to Andrew E. Aplin, PhD.

Patients treated with biologic therapy for inflammatory diseases may not have a higher risk for developing melanoma, a systematic review and meta-analysis found.

Adjuvant pembrolizumab taken for up to 1 year conferred a durable, clinically meaningful RFS benefit for patients with resected high-risk stage III melanoma, according to study results presented during the ASCO20 Virtual Scientific Program.